Scott Requadt

Bio

Scott has over 10 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired in 2005 by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company’s intellectual property group. Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Mr. Requadt is a member of the Board of Directors for TyRx Pharma, Inc. and a Board observer for Biolex Therapeutics, Catabasis Pharmaceuticals, Link Medicine, Oxford Immunotec and Variation Biotechnologies. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar.